This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Volunteers needed for latest UK COVID-19 vaccine study launched in North West London

Volunteers needed for latest UK COVID-19 vaccine study launched in North West London

Volunteers from the North West London area are being asked to sign up to the latest COVID-19 vaccine study to be rolled out across the UK.

The National Institute for Health Research (NIHR)-supported Valneva Phase 2/3 study, will be run at the Chelsea and Westminster Hospital NHS Foundation Trust, and is open to healthy adults who have not had a previous COVID-19 vaccine.

4,000 participants will be recruited across the UK, and everyone involved in the study will receive two active vaccine doses, administered in a four week interval.

Those enrolled in the study over the age of 30 will be randomised to receive two doses of either the Valneva vaccine, or the approved Oxford/AstraZeneca vaccine. Participants aged 18-29 can be enrolled into the study to receive the Valneva vaccine and will not be offered the approved Oxford/AstraZeneca vaccine.

Developed by the specialty vaccine company Valneva, the vaccine is being manufactured at the company’s site in Livingston, West Lothian, and is the only inactivated, adjuvanted (an ingredient to create a stronger immune response) COVID-19 vaccine in clinical development in Europe.

Volunteers for the study will be vaccinated at the beginning of May, and a proportion of potential participants will be identified through the NHS COVID-19 Vaccine Research Registry, which currently has over 480,000 sign-ups. Subject to successful Phase 2/3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021.

If Valneva’s vaccine is shown to be safe and effective, up to 250 million vaccine doses could be supplied to the UK and other countries around the world. As part of the UK government’s vaccine procurement approach, up to 100 million doses of this vaccine have been secured.

 

Professor Adam Finn, Chief Investigator for the Valneva study said:
“Following very encouraging safety and immune response results from our phase 1 study, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine.

“We definitely need more vaccines to help us out of this pandemic and this one is a very promising candidate.”

 

Dr Marta Boffito, Principal Investigator of the trial at Chelsea and Westminster Hospital NHS Foundation Trust, said:
“It's critical to continue clinical studies into COVID-19 vaccines to help find several safe and effective candidates to help protect us all. Volunteers in North West London are still needed to help carry out these studies.

“Anyone interested can visit nhs.uk/researchcontact to sign up to be contacted about taking part in COVID-19 vaccine studies.”

 

Thomas Lingelbach, Chief Executive Officer of Valneva, said:

“As COVID-19 continues to impact people’s daily lives, Valneva remains fully focused on developing another safe and efficacious vaccine solution. The world needs multiple vaccines and we believe that ours has an important role to play - including boosters or potential modifications to address variants.

“The initiation of this trial marks a significant milestone in the development of the only inactivated vaccine candidate against COVID-19 in clinical trials in Europe. We are grateful to the NIHR for its continued support and to everyone who volunteers to make clinical trials possible.”

 

Anyone interested in taking part in this trial can find out more and check their eligibility.